請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/90223完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 湯頌君 | zh_TW |
| dc.contributor.advisor | Sung-Chun Tang | en |
| dc.contributor.author | 傅傳修 | zh_TW |
| dc.contributor.author | Chuan-Hsiu Fu | en |
| dc.date.accessioned | 2023-09-22T17:55:23Z | - |
| dc.date.available | 2023-11-10 | - |
| dc.date.copyright | 2023-09-22 | - |
| dc.date.issued | 2023 | - |
| dc.date.submitted | 2023-08-07 | - |
| dc.identifier.citation | 1. Zhang F, Wang K, Du P, Yang W, He Y, Li T, Mei Z. Risk of Stroke in Cancer Survivors: A Meta-analysis of Population-Based Cohort Studies. Neurology. 2021 Jan 26;96(4):e513-e526. https://doi.org/10.1212/WNL.0000000000011264.
2. Selvik HA, Thomassen L, Logallo N, Næss H. Prior cancer in patients with ischemic stroke: the Bergen NORSTROKE study. J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):919-25. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.07.041. 3. Sanossian N, Djabiras C, Mack WJ, Ovbiagele B. Trends in cancer diagnoses among inpatients hospitalized with stroke. J Stroke Cerebrovasc Dis. 2013 Oct;22(7):1146-50. https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.11.016. 4. Wei YC, Chen KF, Wu CL, Lee TW, Liu CH, Shyu YC, Lin CP. Stroke Rate Increases Around the Time of Cancer Diagnosis. Front Neurol. 2019 Jun 7;10:579. https://doi.org/10.3389/fneur.2019.00579. 5. Cocho D, Gendre J, Boltes A, Espinosa J, Ricciardi AC, Pons J, Jimenez M, Otermin P. Predictors of occult cancer in acute ischemic stroke patients. J Stroke Cerebrovasc Dis. 2015 Jun;24(6):1324-8. https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.02.006. 6. Uemura J, Kimura K, Sibazaki K, Inoue T, Iguchi Y, Yamashita S. Acute stroke patients have occult malignancy more often than expected. Eur Neurol. 2010;64(3):140-4. https://doi.org/10.1159/000316764. 7. Selvik HA, Thomassen L, Bjerkreim AT, Næss H. Cancer-Associated Stroke: The Bergen NORSTROKE Study. Cerebrovasc Dis Extra. 2015 Oct 13;5(3):107-13. https://doi.org/10.1159/000440730. 8. Kim SG, Hong JM, Kim HY, Lee J, Chung PW, Park KY, Kim GM, Lee KH, Chung CS, Bang OY. Ischemic stroke in cancer patients with and without conven-tional mechanisms: a multicenter study in Korea. Stroke. 2010 Apr;41(4):798-801. https://doi.org/10.1161/STROKEAHA.109.571356. 9. Bang OY, Chung JW, Lee MJ, Seo WK, Kim GM, Ahn MJ; OASIS-Cancer Study Investigators. Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms. J Stroke. 2020 Jan;22(1):1-10. https://doi.org/10.5853/jos.2019.02278. 10. Gon Y, Sakaguchi M, Takasugi J, Kawano T, Kanki H, Watanabe A, Oyama N, Terasaki Y, Sasaki T, Mochizuki H. Plasma D-dimer levels and ischaemic lesions in multiple vascular regions can predict occult cancer in patients with cryptogenic stroke. Eur J Neurol. 2017 Mar;24(3):503-508. https://doi.org/10.1111/ene.13234. 11. Kneihsl M, Enzinger C, Wünsch G, Khalil M, Culea V, Urbanic-Purkart T, Payer F, Niederkorn K, Fazekas F, Gattringer T. Poor short-term outcome in patients with ischaemic stroke and active cancer. J Neurol. 2016 Jan;263(1):150-6. https://doi.org/10.1007/s00415-015-7954-6. 12. Navi BB, Singer S, Merkler AE, Cheng NT, Stone JB, Kamel H, Iadecola C, Elkind MS, DeAngelis LM. Recurrent thromboembolic events after ischemic stroke in patients with cancer. Neurology. 2014 Jul 1;83(1):26-33. https://doi.org/10.1212/WNL.0000000000000539. 13. Lau KK, Wong YK, Teo KC, Chang RS, Hon SF, Chan KH, Cheung RT, Li LS, Tse HF, Ho SL, Siu CW. Stroke patients with a past history of cancer are at increased risk of recurrent stroke and cardiovascular mortality. PLoS One. 2014 Feb 11;9(2):e88283. https://doi.org/10.1371/journal.pone.0088283. 14. Navi BB, Iadecola C. Ischemic stroke in cancer patients: A review of an underap-preciated pathology. Ann Neurol. 2018 May;83(5):873-883. https://doi.org/10.1002/ana.25227. 15. Hisada Y, Mackman N. Cancer cell-derived tissue factor-positive extracellular vesicles: biomarkers of thrombosis and survival. Curr Opin Hematol. 2019 Sep;26(5):349-356. https://doi.org/10.1097/MOH.0000000000000521. 16. Mitrugno A, Tassi Yunga S, Sylman JL, Zilberman-Rudenko J, Shirai T, Hebert JF, Kayton R, Zhang Y, Nan X, Shatzel JJ, Esener S, Duvernay MT, Hamm HE, Gruber A, Williams CD, Takata Y, Armstrong R, Morgan TK, McCarty OJT. The role of coagulation and platelets in colon cancer-associated thrombosis. Am J Physiol Cell Physiol. 2019 Feb 1;316(2):C264-C273. https://doi.org/10.1152/ajpcell.00367.2018. 17. Koizume S, Miyagi Y. Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications. Br J Cancer. 2022 Dec;127(12):2099-2107. https://doi.org/10.1038/s41416-022-01968-3. 18. Shao B, Wahrenbrock MG, Yao L, David T, Coughlin SR, Xia L, Varki A, McEver RP. Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. Blood. 2011 Oct 13;118(15):4015-23. https://doi.org/10.1182/blood-2011-07-368514. 19. Lee MJ, Chung JW, Ahn MJ, Kim S, Seok JM, Jang HM, Kim GM, Chung CS, Lee KH, Bang OY. Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study. J Stroke. 2017 Jan;19(1):77-87. https://doi.org/10.5853/jos.2016.00570. 20. Hsu JY, Liu AB. Anticoagulants for cancer-associated ischemic stroke. Ci Ji Yi Xue Za Zhi. 2019 Jul-Sep;31(3):144-148. https://doi.org/10.4103/tcmj.tcmj_55_19. 21. Navi BB, Kasner SE, Elkind MSV, Cushman M, Bang OY, DeAngelis LM. Cancer and Embolic Stroke of Undetermined Source. Stroke. 2021 Mar;52(3):1121-1130. https://doi.org/10.1161/STROKEAHA.120.032002. 22. Sun YE, Na HK, Kwak S, Kim YD, Nam HS, Heo JH. Different Thrombus Histol-ogy in a Cancer Patient with Deep Vein Thrombosis and Recurrent Strokes. J Stroke. 2022 May;24(2):300-302. https://doi.org/10.5853/jos.2021.04140. 23. Yoo J, Kim YD, Park H, Kim BM, Bang OY, Kim HC, Han E, Kim DJ, Heo J, Kim M, Choi JK, Lee KY, Lee HS, Shin DH, Choi HY, Sohn SI, Hong JH, Lee JY, Baek JH, Kim GS, Seo WK, Chung JW, Kim SH, Song TJ, Han SW, Park JH, Kim J, Jung YH, Cho HJ, Ahn SH, Lee SI, Seo KD, Heo JH, Nam HS; SECRET Study Investigators. Immediate and Long-Term Outcomes of Reperfusion Therapy in Pa-tients With Cancer. Stroke. 2021 Jun;52(6):2026-2034. https://doi.org/10.1161/STROKEAHA.120.032380. 24. Verschoof MA, Groot AE, de Bruijn SFTM, Roozenbeek B, van der Worp HB, Dippel DWJ, Emmer BJ, Roosendaal SD, Majoie CBLM, Roos YBWEM, Coutinho JM; MR CLEAN Registry Investigators. Clinical Outcome After Endo-vascular Treatment in Patients With Active Cancer and Ischemic Stroke: A MR CLEAN Registry Substudy. Neurology. 2022 Mar 8;98(10):e993-e1001. https://doi.org/10.1212/WNL.0000000000013316. 25. Caimano D, Letteri F, Capasso F, Limbucci N, Nencini P, Sarti C, Alemseged F, Bigliardi G, Morotti A, Toni D, Zini A, Arba F. Endovascular treatment in patients with acute ischemic stroke and cancer: Systematic review and meta-analysis. Eur Stroke J. 2022 Sep;7(3):204-211. https://doi.org/10.1177/23969873221100897. 26. Duan L, Fu Z, Zhao H, Song C, Tian Q, Dmytriw AA, Regenhardt RW, Sun Z, Guo X, Wang X, Yang B. Outcomes after endovascular thrombectomy for acute ischem-ic stroke patients with active cancer: A systematic review and meta-analysis. Front Neurol. 2022 Oct 20;13:992825. https://doi.org/10.3389/fneur.2022.992825. 27. Letteri F, Pracucci G, Saia V, Sallustio F, Mascolo AP, Da Ros V et al. Endovascu-lar Treatment in Patients With Acute Ischemic Stroke and Comorbid Cancer: Anal-ysis of the Italian Registry of Endovascular Treatment in Acute Stroke. Stroke Vasc Interv Neurol. 2023;3:e000423. https://doi.org/10.1161/SVIN.122.000423 28. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, Dávalos A, Majoie CB, van der Lugt A, de Miquel MA, Donnan GA, Roos YB, Bonafe A, Jahan R, Diener HC, van den Berg LA, Levy EI, Berkhemer OA, Pereira VM, Rempel J, Millán M, Davis SM, Roy D, Thornton J, Román LS, Ribó M, Beumer D, Stouch B, Brown S, Campbell BC, van Oostenbrugge RJ, Saver JL, Hill MD, Jovin TG; HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016 Apr 23;387(10029):1723-31. https://doi.org/10.1016/S0140-6736(16)00163-X. 29. Bacigaluppi M, Semerano A, Gullotta GS, Strambo D. Insights from thrombi re-trieved in stroke due to large vessel occlusion. J Cereb Blood Flow Metab. 2019 Aug;39(8):1433-1451. https://doi.org/10.1177/0271678X19856131. 30. Boeckh-Behrens T, Kleine JF, Zimmer C, Neff F, Scheipl F, Pelisek J, Schirmer L, Nguyen K, Karatas D, Poppert H. Thrombus Histology Suggests Cardioembolic Cause in Cryptogenic Stroke. Stroke. 2016 Jul;47(7):1864-71. https://doi.org/10.1161/STROKEAHA.116.013105. 31. Fu CH, Chen CH, Lin YH, Lee CW, Tsai LK, Tang SC, Shun CT, Jeng JS. Fibrin and Platelet-Rich Composition in Retrieved Thrombi Hallmarks Stroke With Ac-tive Cancer. Stroke. 2020 Dec;51(12):3723-3727. https://doi.org/10.1161/STROKEAHA.120.032069. 32. Park H, Kim J, Ha J, Hwang IG, Song TJ, Yoo J, Ahn SH, Kim K, Kim BM, Kim DJ, Kim YD, Nam HS, Kwon I, Choi HJ, Sohn SI, Lee HS, Heo JH. Histological features of intracranial thrombi in stroke patients with cancer. Ann Neurol. 2019 Jul;86(1):143-149. https://doi.org/10.1002/ana.25495. 33. Heo J, Lee H, Seog Y, Kim S, Baek JH, Park H, Seo KD, Kim GS, Cho HJ, Baik M, Yoo J, Kim J, Lee J, Chang Y, Song TJ, Seo JH, Ahn SH, Lee HW, Kwon I, Park E, Kim BM, Kim DJ, Kim YD, Nam HS. Cancer Prediction With Machine Learning of Thrombi From Thrombectomy in Stroke: Multicenter Development and Validation. Stroke. 2023 Jul 18. https://doi.org/10.1161/STROKEAHA.123.043127. 34. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, Lennon O, Meschia JF, Ngu-yen TN, Pollak PM, Santangeli P, Sharrief AZ, Smith SC Jr, Turan TN, Williams LS. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Tran-sient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. https://doi.org/10.1161/STR.0000000000000375. 35. von Kummer R, Broderick JP, Campbell BC, Demchuk A, Goyal M, Hill MD, Treurniet KM, Majoie CB, Marquering HA, Mazya MV, San Román L, Saver JL, Strbian D, Whiteley W, Hacke W. The Heidelberg Bleeding Classification: Classifi-cation of Bleeding Events After Ischemic Stroke and Reperfusion Therapy. Stroke. 2015 Oct;46(10):2981-6. https://doi.org/10.1161/STROKEAHA.115.010049. 36. Wahrenbrock M, Borsig L, Le D, Varki N, Varki A. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest. 2003 Sep;112(6):853-62. https://doi.org/10.1172/JCI18882. 37. Strasenburg W, Jóźwicki J, Durślewicz J, Kuffel B, Kulczyk MP, Kowalewski A, Grzanka D, Drewa T, Adamowicz J. Tumor Cell-Induced Platelet Aggregation as an Emerging Therapeutic Target for Cancer Therapy. Front Oncol. 2022 Jun 23;12:909767. https://doi.org/10.3389/fonc.2022.909767. 38. Dudiki T, Veleeparambil M, Zhevlakova I, Biswas S, Klein EA, Ford P, Podrez EA, Byzova TV. Mechanism of Tumor-Platelet Communications in Cancer. Circ Res. 2023 May 26;132(11):1447-1461. https://doi.org/10.1161/CIRCRESAHA.122.321861. 39. Palacios-Acedo AL, Mège D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Platelets, Thrombo-Inflammation, and Cancer: Collaborating With the Enemy. Front Immunol. 2019 Jul 31;10:1805. https://doi.org/10.3389/fimmu.2019.01805. 40. Braun A, Anders HJ, Gudermann T, Mammadova-Bach E. Platelet-Cancer Inter-play: Molecular Mechanisms and New Therapeutic Avenues. Front Oncol. 2021 Jul 12;11:665534. https://doi.org/10.3389/fonc.2021.665534. 41. Anvari S, Osei E, Maftoon N. Interactions of platelets with circulating tumor cells contribute to cancer metastasis. Sci Rep. 2021 Jul 29;11(1):15477. https://doi.org/10.1038/s41598-021-94735-y. 42. Bozhao Li, Zefang Lu, Zhenlin Yang, Xiuping Zhang, Meiqi Wang, Tianjiao Chu, Peina Wang, Feilong Qi, Greg J. Anderson, Ershuai Jiang, Zhenchuan Song, Guangjun Nie, Suping Li. Monitoring circulating platelet activity to predict cancer-associated thrombosis, Cell Reports Methods, 2023,100513, ISSN 2667-2375. https://doi.org/10.1016/j.crmeth.2023.100513. 43. Jolugbo P, Ariëns RAS. Thrombus Composition and Efficacy of Thrombolysis and Thrombectomy in Acute Ischemic Stroke. Stroke. 2021 Mar;52(3):1131-1142. https://doi.org/10.1161/STROKEAHA.120.032810. 44. Shimizu H, Hatakeyama K, Saito K, Shobatake R, Takahashi N, Deguchi J, Tokunaga H, Shimada K, Nakagawa I, Myochin K, Sakai K, Kubo M, Yamashita A, Obayashi C, Sugie K, Matsumoto M. Age and composition of the thrombus retrieved by mechanical thrombectomy from patients with acute ischemic stroke are associated with revascularization and clinical outcomes. Thromb Res. 2022 Nov;219:60-69. https://doi.org/10.1016/j.thromres.2022.09.004. 45. Staessens S, Fitzgerald S, Andersson T, Clarençon F, Denorme F, Gounis MJ, Hacke W, Liebeskind DS, Szikora I, van Es A, Brinjikji W, Doyle KM, De Meyer SF. Histological stroke clot analysis after thrombectomy: Technical aspects and recommendations. Int J Stroke. 2020 Jul;15(5):467-476. https://doi.org/10.1177/1747493019884527. 46. Costamagna G, Bonato S, Corti S, Meneri M. Advancing Stroke Research on Cerebral Thrombi with Omic Technologies. Int J Mol Sci. 2023 Feb 8;24(4):3419. https://doi.org/10.3390/ijms24043419. 47. Feldman S, Gupta D, Navi BB, Grace Ho KW, Willeit P, Devlin S, Bolton KL, Arcila ME, Mantha S. Tumor Genomic Profile Is Associated With Arterial Thromboembolism Risk in Patients With Solid Cancer. JACC CardioOncol. 2023 Apr 18;5(2):246-255. https://doi.org/10.1016/j.jaccao.2023.01.009. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/90223 | - |
| dc.description.abstract | 高纖維蛋白及血小板之血栓常見於癌症中風病人發生大血管中風後取出的血栓表徵，癌症引起之高凝血狀態(hypercoagulable state)被認為為主要之病生理機轉。高纖維蛋白及血小板之血栓是否能反映癌症中風病人之臨床預後及作為評估短期內再中風及死亡之風險為此篇研究目的。
本研究之個案來自台大醫院自2015年3月至2021年11月因大血管阻塞且接受取栓術之缺血性中風之病人，並分為活躍性癌症(active cancer), 非活躍性癌症及非癌症三組。將所有取出的血栓進行常規Hematoxylin and eosin染色並針對高纖維蛋白及血小板占血栓區域之比例進行定量，並與90天內發生中風復發或死亡之臨床預後進行關聯性分析。 在本研究納入之420位接受取拴術且含血栓供組織分析的個案中，有50位為活躍性癌症(active cancer), 23位非活躍性癌症(non-active cancer)及347位非癌症病人。取出之血栓中，在活躍性癌症病人中的纖維蛋白及血小板之比例較其他兩組為高(P<0.001)。在活躍性癌症病人中， 90天內發生中風復發或死亡之病人，其纖維蛋白及血小板之血栓比例也較未發生中風復發或死亡之病人較高 (血栓內纖維蛋白及血小板比例：86.4% vs. 55.8%, P= 0.008)；在非癌症病人則並未觀察到此現象。 經校正年齡、性別及遠處轉移後，高纖維蛋白及血小板之血栓於活躍性癌症之病人仍顯著與90天內之中風復發或死亡相關。(adjusted odds ratio=1.03, 95% CI: 1.00-1.06, P=0.028) 本研究顯示，高纖維蛋白及血小板之血栓可能為癌症病人併中風接受動脈血栓移除術後之中風復發或死亡之重要預後指標。 | zh_TW |
| dc.description.abstract | Background and Purpose Fibrin+platelet-rich clot is characteristic of cancer related stroke. Cancer-related hypercoagulability state is considered the main patho-mechanism. The main purpose of this study is to investigate the correlation between clot composition and short-term clinical outcomes in patients with active cancer after stroke.
Methods Acute ischemic stroke patients receiving endovascular thrombectomy between March 2015 and November 2021 were included, and were divided into active cancer, non-active cancer and without cancer groups. Clots underwent hematoxylin and eosin staining and the percentages of fibrin+platelet were quantified. Stroke recurrence was defined as newly developed neurological deficits 90 days from the index stroke event. Results A total of 420 patients with retrieved clots were included, which comprised of 50 patients with active cancer, 23 patients with non-active cancer and 347 patients with-out cancer. Higher fibrin+platelet composition was observed in active cancer group compared to the other two groups. (all P<0.001) In patients with active cancer, fi-brin+platelet percentage in retrieved thrombi was higher in those with composite out-come than those without (86.4% vs. 55.8%, P= 0.008), while no such difference was ob-served in patients without cancer. After adjustment of age, sex and distant metastases, the fibrin+platelet percentage was significantly associated with stroke recurrence or mor-tality at 90 days in active cancer group [adjusted odds ratio=1.03 (1.00-1.06], P=0.028]. Conclusions Thrombi with higher percentage of fibrin+platelet may predict stroke re-currence or mortality at 90 days among stroke patients with active cancer after EVT. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-09-22T17:55:23Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2023-09-22T17:55:23Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要 iii Abstract iv Table of Contents v List of Figures vii List of Tables viii Chapter 1. Introduction 1 1.1 Cancer-related hypercoagulability and stroke 1 1.2 Treatment and prognosis in cancer-related stroke 2 1.3 Thrombus composition and stroke etiology in the era of endovascular thrombectomy 3 1.4 Thrombus composition in cancer-related stroke 4 1.5 Hypothesis and study objectives 4 Chapter 2. Material and Methods 6 2.1 Patient selection 6 2.2 Clinical data collection 6 2.3 Study outcomes 7 2.4 Histological characterization and quantification of thrombu 7 2.5 Statistical analysis 8 Chapter 3. Results 10 3.1 Clinical characteristics among three group 10 3.2 Demographics by outcomes within active cancer group 11 3.3 Thrombus composition and outcomes in patients with active cancer 12 3.4 Thrombus composition and outcomes in patients without cancer 14 Chapter 4. Discussion 15 4.1 High fibrin+platelet thrombi represent poor clinical outcomes in stroke patients with active cancer receiving endovascular thrombectomy 15 4.2 High fibrin+platelet thrombi as a surrogate marker of hypercoagulability in various cancer stage 16 4.3 Platelets as the central role in arterial thrombosis and non-bacterial infective en-docarditis in cancer-related stroke 17 4.4 Associations of thrombus composition and clinical outcomes in patient without cancer 18 4.5 Study limitation 19 Chapter 5. Conclusions and future perspectives 20 5.1 Implication of thrombus composition and clinical outcomes of cancer patients receiving endovascular thrombectomy 20 5.2 Future perspectives in cancer-related stroke 21 References 22 Appendix 1. Figures and Tables 31 | - |
| dc.language.iso | en | - |
| dc.subject | 癌症 | zh_TW |
| dc.subject | 中風 | zh_TW |
| dc.subject | 血栓移除術 | zh_TW |
| dc.subject | 血栓 | zh_TW |
| dc.subject | 凝血異常 | zh_TW |
| dc.subject | thrombectomy | en |
| dc.subject | stroke | en |
| dc.subject | coagulopathy | en |
| dc.subject | cancer | en |
| dc.subject | thrombus | en |
| dc.title | 高纖維蛋白及血小板之血栓與癌症病人經動脈血栓移除術後中風復發及死亡之相關性研究 | zh_TW |
| dc.title | High fibrin+platelet thrombus is associated with early stroke recurrence and mortality after endovascular thrombectomy in patients with active cancer | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 111-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 楊偉勛;鄭建興 | zh_TW |
| dc.contributor.oralexamcommittee | Wei-Shiung Yang;Jiann-Shing Jeng | en |
| dc.subject.keyword | 中風,血栓移除術,血栓,癌症,凝血異常, | zh_TW |
| dc.subject.keyword | stroke,thrombectomy,thrombus,cancer,coagulopathy, | en |
| dc.relation.page | 46 | - |
| dc.identifier.doi | 10.6342/NTU202303227 | - |
| dc.rights.note | 同意授權(限校園內公開) | - |
| dc.date.accepted | 2023-08-07 | - |
| dc.contributor.author-college | 醫學院 | - |
| dc.contributor.author-dept | 臨床醫學研究所 | - |
| dc.date.embargo-lift | 2023-12-01 | - |
| 顯示於系所單位： | 臨床醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-111-2.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務） | 2.28 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。